Volltextsuche
Hinweis: Bitte geben Sie einen Suchbegriff ein, z.B. "BMW", um alle Analysen und News über BMW aufgelistet zu bekommen, die innerhalb der Site von AktienCheck vorhanden sind! Zusätzlich können Sie noch eine Zeitspanne auswählen.
Suchergebnisse: (3693236 Ergebnisse gefunden) Es.
| Datum | Thema | |
|---|---|---|
| 13:30 | Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors | |
| SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D., has been appointed to the Company’s Board of Directors. Dr. Chan recently served as Senior Vice President, Research Biology during a distinguished 25 year career at Genentech. [...] | ||
| 13:30 | FirstService Reports First Quarter Results | |
| FirstService Residential Operating Performance Contributes to Earnings Growth FirstService Residential Operating Performance Contributes to Earnings Growth. [...] | ||
| 13:30 | Plato Gold Reports on 2025 Year-End Results, Announces Appointment of New CFO and Corp. Secretary | |
| Toronto, ON, April 23, 2026 (GLOBE NEWSWIRE) -- Plato Gold Corp. (TSX-V: PGC) (OTCQB: NIOVF) (Frankfurt: 4Y7 or WKN: A0M2QX) (“Plato” or the “Company”) an exploration company with a portfolio of properties in Northern Ontario and Santa Cruz, Argentina, is pleased to report its financial resul. [...] | ||
| 13:30 | Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™ | |
| HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announced today the initiation of manufacturing activities and technology transfer with SpectronRx under a previously executed Master Services Agreement (MSA), in support of late-stage clinical manufacturing of Rhenium-186 and REYOBIQ. [...] | ||
| 13:30 | Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit | |
| Marvel Biosciences to participate in 2nd Neuroscience Innovation Partnering & Licensing Summit, allowing Marvel to showcase its progress on global stage. [...] | ||
| 13:30 | Applied Materials to Report Fiscal Second Quarter 2026 Results on May 14, 2026 | |
| SANTA CLARA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Applied Materials, Inc. today announced that it will hold its fiscal second quarter 2026 earnings conference call on Thursday, May 14, 2026, at 4:30 p.m. ET / 1:30 p.m. PT.. [...] | ||
| 13:30 | Kelly Announces First-Quarter 2026 Conference Call | |
| TROY, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Kelly, a leading global specialty talent solutions provider, will release its first-quarter earnings before the market opens on Thursday, May 7, 2026. In conjunction with its earnings release, Kelly will publish a financial presentation and host a live webcast of a conference call with financial analysts at 9 a.m. [...] | ||
| 13:30 | Innventure Further Details Its Capital Allocation Strategy | |
| ORLANDO, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- Innventure, Inc. (NASDAQ:INV) (“Innventure”), an industrial growth conglomerate that partners with leading multinationals, today further detailed its capital allocation strategy. The additional detail follows increased investor interest in how Innv. [...] | ||
| 13:26 | Fiskars Aktie: Cashflow-Wende überzeugt | |
| Der erste Quartalsbericht 2026 hat die Anleger sichtlich erleichtert. Die Fiskars-Aktie legte am Mittwoch um über fünf Prozent zu und markierte damit den stärksten Handelstag seit fast zwei Jahren. Der Grund: Ein operatives Ergebnis, das Analysten deutlich überraschte. [...] | ||
| 13:25 | UBS Aktie: Regulierungsstreit eskaliert | |
| Die Schweizer Großbank hat deutliche Worte gefunden. Das neue Regulierungspaket des Bundesrats sei „extrem", international nicht abgestimmt und ignoriere die Mehrheit der eingereichten Bedenken — so die offizielle Stellungnahme der UBS. Die Reaktion ließ an der Börse nicht lange auf sich warten: Die Aktie verlor zeitweise rund 2,8 Prozent auf 32,60 Franken. [...] |
